

#### References:

1. Summary of product characteristics in KSA on Saudi Drugs Information system (SDI) website: (<https://sdi.sfda.gov.sa/>).

FlexTouch® and Awiqli® are registered trademarks of Novo Nordisk A/S © Novo Nordisk A/S, Novo Álle, DK-2880 Bagsværd, Denmark; approval date: May 2024

#### Disclaimer:

- This educational guide is designed for informational and risk minimisation purposes only and should not be construed as promotional or marketing material.

#### Kindly report side effects through the following channels:


- Saudi Food & Drug Authority (SFDA):  
SFDA Call Center: 19999  
E-mail: [npc.drug@sfda.gov.sa](mailto:npc.drug@sfda.gov.sa)  
Website: <http://ade.sfda.gov.sa/>

- Novo Nordisk Saudi Arabia:  
E-mail: [nngulfsafety@novonordisk.com](mailto:nngulfsafety@novonordisk.com)  
Website: <https://www.novonordisk.com.sa/>

# Introducing Awiqli® insulin icodec injection

## Patient Guide: Important Risk Minimization Information for Safe Use

This educational material has been approved  
by The Executive Directorate of Pharmacovigilance, at SFDA



You have been prescribed Awiqli® for the treatment of your diabetes. This booklet aims to provide information about Awiqli® to help you take your once weekly treatment correctly and avoid medication errors.

For more information about the product, please read the patient insert leaflet.



## What is Awiqli® and what is it used for?

- Awiqli® is a once-weekly basal insulin analogue used to treat diabetes in adults. It is a long-acting insulin that you only inject once a week to help control your blood sugar levels.
- Awiqli® should only be used once a week. Please ensure you strictly adhere to the weekly dosing regimen as prescribed by your doctor.



## What are medication errors?


While using Awiqli® it is important for you to understand the possible occurrence of medication errors.

- Medication errors can occur due to accidental mix-ups between Awiqli® and other insulins, particularly rapid-acting insulins.
- Medication errors can also occur due to incorrect administration of Awiqli® doses during switch from daily basal insulins to once a week Awiqli®.
- Please speak to your doctor to identify the design differences between Awiqli® and other insulin pens.
- Before using Awiqli® carefully read the instructions in the package leaflet, available in the Awiqli® package.



## Avoiding mix-ups:

- If you use more than one insulin always ensure you use the right insulin by checking the insulin's name and concentration before each injection. Before injecting Awiqli® make sure that your pen label reads Awiqli® 700 units/mL.
- The pen can provide a dose of 10 to 700 units of Awiqli® in 1 injection, in steps of 10 units. Always use the dose counter and the dose pointer to select the dose. Do not count the pen clicks to select the dose.
- In contrast to other insulin pens that allow dose adjustments of 1 or 2 units per step, the Awiqli® pen allows dose adjustments of 10 units at a time.
- Always check how many units were selected before injecting the weekly insulin.
- If you are blind or have poor eyesight and cannot follow instructions, do not use the pen without assistance. Seek help from someone with good eyesight who knows how to use the Awiqli® pen.



## Switching from other basal insulins to Awiqli®

- When switching from once or twice daily insulins to Awiqli®, your doctor will decide your weekly dose based on your current basal insulin dose and blood sugar levels, as well as other factors.
- Your doctor may decide to prescribe an increased first dose of Awiqli® based on your blood glucose control needs. This increased dose is for the first injection only and should not be used for the second and following injections.
- Before injecting, always check that you have the correct prescribed dose of Awiqli®, particularly for the first and second injections, and always check how many units were selected.
- During the switch to Awiqli®, and in the weeks after the switch, you should measure your blood sugar levels more frequently.



## General information:

- If you experience any medication errors or side effects while using Awiqli®, report them immediately to Novo Nordisk (contact details provided) or local authorities. Seek help from your doctor, pharmacist, or nurse if needed.
- If you take more units of Awiqli® than you should, your blood sugar level may become too low. Check your blood sugar and if required, eat glucose tablets or other high sugar snacks like sweets, biscuits, or fruit juice.
- See the advice at the end of the package leaflet, available in the Awiqli® package, to know what to do if your blood sugar level gets too high or low.
- To avoid dosing errors or potential overdose, please don't use a syringe to remove the solution from the pen.
- If you have any questions speak to your doctor.